L01XX33 - Celecoxib |
Propably not porphyrinogenic |
PNP |
Rationale
Celecoxib is a substrate of CYP2C9, but does not inhibit CYP2C9 or 3A4. No reports of CYP-inducing effect.
Chemical description
Celecoxib is a diaryl substituted pyrazole derivative containing a sulfonamide substituent.
Therapeutic characteristics
Celecoxib is a NSAID used as an adjunct to standard therapy to reduce the number of adenomatous colorectal polyps in patients with familial adenomatous polyposis. It is administered orally. Common adverse reactions of celecoxib that can be confused with an acute porphyric attack are abdominal pain, dyspepsia, diarrhoea, and insomnia.
Metabolism and pharmakokinetics
The metabolism of celecoxib is mediated mainly by the cytochrome P450 isoenzyme CYP2C9. Minor substrate of CYP3A4 (Rendic, 2002; Zhou, 2007). Less than 3 % recovered as unchanged rug. Inhibitor of the isoenzyme CYP2D6, but the drug does not inhibit CYP2C9, CYP2C19, or CYP3A4. No observations pointing to CYP-induction in clinical use. Not listed as CYP-inducer.
Personal communication
One report of uneventful use of celecoxib as an NSAID (C.Andersson; patient report).
IPNet drug reports
Uneventful use of celecoxib as an NSAID (ATC-code: M01AH01), reported in 3 patients with acute porphyria.
References
- Scientific articles
- Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448. #1025
- Zhou, S.F., Xue, C.C., et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29(6):687:710. #1027
- Drug reference publications
- McEvoy GK, editor. Celecoxib. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (21.06.10). #2113
- Sweetman SC, editor. Martindale: The complete drug reference. Celecoxib. Pharmaceutical Press 2009. #2114
Similar drugs
© NAPOS 2024